The resolution of the Expert Council on the Diagnosis, Treatment, and Prevention of Symptoms of Depression in Outpatients with New Coronavirus Infection

COVID-19, coronavirus, post-covid syndrome, pandemic, prevention, treatment, anxiety, depression, prognosis

1. Aleksandrovskii Yu. A., Chekhonin V. P. Klinicheskaya immunologiya pogranichnykh psikhicheskikh rasstroistv. M.: GEOTAR-Media. 2005. (In Russ.)

2. Alexandrovsky, Yu A. Ratsional’naya farmakoterapiya v psikhiatricheskoi praktike: rukovodstvo dlya praktikuyushchikh vrachei / pod obshch. red. Yu. A. Aleksandrovskogo, NG Neznanova. Moskva: Litterra. 2014. 1080 p. (In Russ.) ISBN 978-5-4235-0134-1.

3. Alexeeva N. T., Sokolov D. A., Nikityuk D. B., et al. Molecular and cellular mechanisms of central nervous system alteration in COVID-19. Zhurnal anatomii i gistopatologii. 2020; 9 (3): 72-85. (In Russ.) doi:10.18499/2225-7357-2020-9-3-72-85

4. Volel B. A., Petelin D. S., Romanov D. V, et al. Algoritmy diagnostiki i terapii psikhicheskikh rasstroistv v obshchemeditsinskoi praktike. M. 2020 (In Russ.)

5. Kekelidze Z. I., Chekhonin V. P. Kriticheskie sostoyaniya v psikhiatrii (klinicheskie i immuno-khimicheskie aspekty). М. 1997. 362 р. (In Russ.)

6. Martynov M. Yu., Bogolepova A. N., Yasamanova A. N. Endothelial dysfunction in COVID-19 and cognitive impairment. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2021; 121 (6): 93–99. (In Russ.) doi: 10.17116/jnevro202112106193

7. Mosolov S. N. Long-term psychiatric sequelae of SARS-CoV-2 infection. Sovrem. ter. psih. rasstrojstv. Sovremennaya terapiya psikhicheskikh rasstroistv. 2021; (3): 2–23. (In Russ.) doi: 10.21265/PSYPH.2021.31.25.001

8. Oganov R. G., Ol’binskaya L. I., Smulevich A. B. et al. Depressii i rasstroistva depressivnogo spektra v obshchemeditsinskoi praktike. Rezul’taty programmy KOMPAS. Kardiologiya 2004; 1: 48–54. (In Russ.)

9. Rukavishnikov G. V., Neznanov N. G., Martynov A. I., et al. Terapiya depressii u patsientov s komorbidnymi somaticheskimi zabolevaniyami. Terapiya. 2020; 6: 76-83. (In Russ.)

10. Khasanova D. R., Zhitkova Yu. V., Vaskaeva G. R. Post-covid syndrome: a review of pathophysiology, neuropsychiatric manifestations and treatment perspectives. Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (3): 93–98. (In Russ.) doi: 10.14412/2074-2711-2021-3-93-98

11. Alpert O., Begun L., Garren P., et al. Cytokine storm induced new onset depression in patients with COVID-19. A new look into the association between depression and cytokines -two case reports. Brain Behav Immun Health. 2020; 9: 100173. doi: 10.1016/j.bbih.2020.100173. PMID: 33163979.

12. Andersson N. W., Goodwin R. D., Okkels N., et al. Depression and the risk of severe infections: prospective analyses on a nationwide representative sample. Int J Epidemiol. 2016; 45 (1): 131-9. doi: 10.1093/ije/dyv333. PMID: 26708840.

13. Badenoch J. B., Rengasamy E. R., Watson C., et al. Persistent neuropsychiatric symptoms after COVID-19: a systematic review and meta-analysis. Brain Commun. 2021;4 (1): fcab297. doi: 10.1093/braincomms/fcab297. PMID: 35169700.

14. Carta M. G., Pala A. N., Finco G., et al. Depression and cerebrovascular disease: could vortioxetine represent a valid treatment option? Clin Pract Epidemiol Ment Health. 2015; 11: 144-149. doi: 10.2174/1745017901511010144. PMID: 25893002.

15. Chen G., Lee R., Højer A. M., et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013; 33 (10): 727-736. doi: 10.1007/s40261-013-0117-6. PMID: 23975654.

16. Chin C. N., Zain A., Hemrungrojn S., et al. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin. 2018; 34 (11): 1975-84. doi: 10.1080/03007995.2018.1477746. PMID: 29768955.

17. COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398 (10312): 1700-1712. doi: 10.1016/S0140-6736(21)02143-7. PMID: 34634250.

18. Deng J., Zhou F., Hou W., et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021; 1486 (1): 90-111. doi: 10.1111/nyas.14506. PMID: 33009668.

19. Helms J., Kremer S., Merdji H., et al. Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med. 2020; 382 (23): 2268-2270. doi: 10.1056/NEJMc2008597. PMID: 32294339.

20. Katona C. L., Katona C. P. New generation multimodal antidepressants: focus on vortioxetine for major depressive disorder. Neuropsychiatr Dis Treat. 2014; 10: 349-354. doi: 10.2147/NDT.S39544. PMID: 24570588.

21. Kreye J., Reincke S. M., Prüss H. Do cross-reactive antibodies cause neuropathology in COVID-19? Nat Rev Immunol. 2020; 20: 645–646. doi: 10.1038/s41577-020-00458-y.

22. Mahableshwarkar A. R., Zajecka J., Jacobson W., et al. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015; 40 (8): 2025-2037. doi: 10.1038/npp.2015.52. PMID: 25687662.

23. Mahmoudi H., Saffari M., Movahedi M., et al. A mediating role for mental health in associations between COVID-19-related self-stigma, PTSD, quality of life, and insomnia among patients recovered from COVID-19. Brain Behav. 2021; 11 (5): e02138. doi: 10.1002/brb3.2138. PMID: 33811451.

24. Masand P. S. Tolerability and adherence issues in antidepressant therapy. Clin Ther. 2003; 25 (8): 2289-2304. doi: 10.1016/s0149-2918(03)80220-5. PMID: 14512135.

25. Mazza M., Lotrionte M., Biondi-Zoccai G., et al. Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol. 2010; 24 (12): 1785-1792. doi: 10.1177/0269881109348176. PMID: 19965939.

26. Meinhardt J., Radke J., Dittmayer C., et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021; 24 (2): 168-175. doi: 10.1038/s41593-020-00758-5. PMID: 33257876.

27. Miners S., Kehoe P. G., Love S. Cognitive impact of COVID-19: Looking beyond the short term. Alzheimer’s Res. Ther. 2020; 12: 170. doi: 10.1186/s13195-020-00744-w.

28. Pizzi C., Rutjes A. W., Costa G. M., et al. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol. 2011; 107 (7): 972-979. doi: 10.1016/j.amjcard.2010.11.017. PMID: 21256471.

29. Raman B., Philip M., Tunnicliffe E. M. et al. Mediumterm effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine. 2021; 31: 100683. doi: 10.1016/j.eclinm.2020.100683. PMID: 33490928.

30. Rayner C., Campbell R. Long Covid Implications for the workplace. Occup Med (Lond). 2021; 71 (3): 121-3. doi: 10.1093/occmed/kqab042. PMID: 33822179.

31. Roest A. M., Martens E. J., de Jonge P., et al. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. 2010; 56 (1): 38-46. doi: 10.1016/j.jacc.2010.03.034. PMID: 20620715.

32. Sanchez C., Asin K. E., Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015; 145: 43-57. doi: 10.1016/j.pharmthera.2014.07.001. PMID: 25016186.

33. Sorokin M. Y., Kasyanov E. D., Rukavishnikov G. V., et al. Determinants of Stress Levels and Behavioral Reactions in Individuals With Affective or Anxiety Disorders During the COVID-19 Pandemic in Russia. Front Sociol. 2022; 7: 870421. doi: 10.3389/fsoc.2022.870421. PMID: 35865268.

34. Sorokin M. Y., Kasyanov E. D., Rukavishnikov G. V., et al. Structure of anxiety associated with СOVID-19 pandemic: the online survey results. Bulletin of RSMU. 2020; (3: 70–77. doi: 10.24075/brsmu.2020.030

35. Spina E., Santoro V., D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008; 30 (7): 1206-1227. doi: 10.1016/s0149-2918(08)80047-1. PMID: 18691982.

36. Sudre C. H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021; 27 (4): 626-631. doi: 10.1038/s41591-021-01292-y. PMID: 33692530.

37. Taquet M., Luciano S., Geddes J. R., et al. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021; 8 (2): 130-140. doi: 10.1016/S2215-0366(20)30462-4. PMID: 33181098.

38. Tenforde M. W., Kim S. S., Lindsell C. J., et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69 (30): 993-998. doi: 10.15585/mmwr.mm6930e1. PMID: 32730238.

39. Tyapaeva A. R., Semenova O. N., Tashkenbaeva E. N., et al. Clinical, laboratory and psychological aspects of moderate COVID-19 in cardiovascular patients one month after discharge from the hospital. Russian Journal of Cardiology. 2021; 26 (4S): 4603. doi: 10.15829/1560-4071-2021-4603

40. Varga Z., Flammer A. J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417-1418. doi: 10.1016/S0140-6736(20)30937-5. PMID: 32325026.

41. Xie Y., Xu E., Al-Aly Z. Risks of mental health outcomes in people with covid-19: cohort study BMJ 2022; 376 :e068993. doi:10.1136/bmj-2021-068993.

42. Xu E., Xie Y., Al-Aly Z. Long-term neurologic outcomes of COVID-19. Nat Med. 2022. doi: 10.1038/s41591-022-02001-z. PMID: 36138154.

43. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364 (9438): 937-952. doi: 10.1016/S0140-6736(04)17018-9. PMID: 15364185.